Moderna vaccinates first participant in phase 2 trial of Omicron-specific booster as study finds that antibodies fall 6-fold over 6 months

Moderna announced Wednesday that the first participant has been dosed in the company's Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant.

Moderna promises to share its data from the trial with public health leaders so they can make evidence-based decisions on the best booster strategy against the coronavirus going forward. A study published Wednesday says the Moderna Covid-19 booster shot remains durable against the Omicron variant, but the antibody protection wanes and is six times lower six months after getting boosted.

Research teams from Moderna, Duke University, Emory University, the Fred Hutchinson Cancer Research Center, the Baylor College of Medicine, the University of Maryland School of Medicine and the National Institutes of Health looked at blood samples from adults who had two doses of the Moderna vaccine, as well as those who also had a booster dose. Some of those were boosted with the 50-microgram dose and some at 100-μg levels. The current booster is authorized at the 50-μg level.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pfizer-BioNTech begin Omicron vaccine trialThe company’s head of vaccine research Kathrin Jansen said in a statement that while current data showed that boosters against the original Covid strain continued to protect against severe outcomes with Omicron, the company was acting out of caution. Why would they spend so much money and time creating another one if the one they are using is supposedly working? This is nonsense.
Source: manilabulletin - 🏆 25. / 51 Read more »